Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Apr;84(4):345-52.
doi: 10.1016/S0025-6196(11)60544-2.

Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease

Affiliations
Review

Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease

Dean G Karalis. Mayo Clin Proc. 2009 Apr.

Abstract

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the United States, and a high concentration of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for CAD. Current guidelines recommend the use of statins to lower LDL-C levels for the primary prevention of CAD based on an individual's risk factor profile and baseline LDL-C level. For moderaterisk individuals, those with 2 or more major risk factors for CAD and a Framingham risk score of 10% to 20%, the recommendation is to use a statin to lower LDL-C levels to less than 130 mg/dL. However, up to 40% of individuals who develop CAD have LDL-C levels lower than this cutoff. In 2004, the National Cholesterol Education Program Adult Treatment Panel III guidelines were updated to include an LDL-C goal of less than 100 mg/dL for individuals at moderately high risk of developing CAD. The guidelines identified several risk factors that when present would favor the use of pharmacological therapy to achieve this more aggressive LDL-C goal. This review evaluates the evidence supporting an LDL-C target of less than 100 mg/dL for moderately high-risk individuals and reviews those risk factors that when present help identify patients who would benefit from achieving this lower LDL-C goal. English-language publications in MEDLINE and references from relevant articles published between January 1, 1980, and November 30, 2008, were reviewed. Main keywords searched were coronary artery disease, hyperlipidemia, statins, cardiac risk factors, inflammatory markers, metabolic syndrome, and coronary artery calcium.

PubMed Disclaimer

Figures

FIGURE.
FIGURE.
Treatment algorithm for the primary prevention of coronary artery disease (CAD). The main changes in the updated National Cholesterol Education Program Adult Treatment Panel III guidelines are the lower low-density lipoprotein cholesterol (LDL-C) goal of less than 100 mg/dL for individuals with 2 or more CAD risk factors and a Framingham risk score of 10% to 20%. The presence of multiple or severe risk factors, an elevated level of C-reactive protein (CRP), or other risk factors identified in the updated guidelines justify more intensive LDL-C level lowering with drug therapy to achieve a lower LDL-C goal of less than 100 mg/dL. CAC = coronary artery calcium; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides. SI conversion factors: To convert cholesterol (HDL-C, LDL-C) levels to mmol/L, multiply by 0.0259; to convert CRP values to nmol/L, multiply by 9.524; to convert TG values to mmol/L, multiply by 0.0113.

Comment in

References

    1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008January;117(4):e25-e146 Epub 2007 Dec 17 - PubMed
    1. Downs JR, Clearfield M, Weis S, et al. AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279(20):1615-1622 - PubMed
    1. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-1158 - PubMed
    1. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-1307 - PubMed
    1. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins [published corrections appear in Lancet. 2005;366(9494):1358 and 2008;371(9630):2084] Lancet 2005October8;366:(9493) 1267-1278 Epub 2005 Sep 27 - PubMed

Publication types